| PLB-1004 |
PLB-1004 |
Phase 3 Clinical |
Beijing Avistone Pharmaceuticals Biotechnology Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
| Mefatinib |
|
Phase 3 Clinical |
Suzhou Maitai Bio-Technology Co Ltd |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
| Recombinant anti-HER2 humanized monoclonal antibody (Shanghai Institute of Biological Products) |
SIBP-01 |
Phase 3 Clinical |
Shanghai Institute Of Biological Products Co Ltd |
Stomach Neoplasms; Breast Neoplasms |
Details
|
| Anvatabart opadotin |
ARX-788; NCB-001 |
Phase 3 Clinical |
|
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Bile Duct Neoplasms; Metastatic breast cancer |
Details
|
| Hemay-022 |
Hemay-022 |
Phase 3 Clinical |
Tianjin Hemay Pharmaceutical Co Ltd, Xiajiang Hemei Pharmaceutical Co Ltd |
Breast Neoplasms; Foodborne Diseases |
Details
|
| Trastuzumab biosimilar (Hanwha Biologics) |
HD-201 |
Phase 3 Clinical |
Hanwha Biologics |
Breast Neoplasms |
Details
|
| Pertuzumab biosimilar（Hisun Pharm） |
HS-627; HS627 |
Phase 3 Clinical |
Zhejiang Hisun Pharmaceutical Co Ltd, Beijing Mabworks Biotech Co Ltd |
Breast Neoplasms |
Details
|
| Trastuzumab rezetecan |
SHR-A1811 |
Phase 3 Clinical |
Jiangsu Hengrui Medicine Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd |
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Salivary Gland Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Metastatic breast cancer; HR-positive breast cancer; Carcinoma, Non-Small-Cell Lung |
Details
|
| Trastuzumab monomethyl auristatin F |
FS-1502; LCB14-0110; LCB-14-0110 |
Phase 3 Clinical |
Legochembio |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung |
Details
|
| Varlitinib Ditosylate |
SPS-4370; ASLAN-001; ARRY-334543; ARRY-543; QBT-01 |
Phase 3 Clinical |
Array Biopharma |
Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Bile Duct Neoplasms |
Details
|
| Anbenitamab |
KN-026 |
Phase 3 Clinical |
Suzhou Alphamab Co Ltd |
Biliary Tract Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Metastatic breast cancer; Lymphoma; Gastrointestinal Neoplasms |
Details
|
| Coprelotamab |
GB-221 |
Phase 3 Clinical |
Genor Biopharma Co Ltd |
Breast Neoplasms |
Details
|
| Trastuzumab vedotin |
MRG-002 |
Phase 3 Clinical |
Shanghai Miracogen Inc |
Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Transitional Cell; Breast Neoplasms; Bile Duct Neoplasms; Metastatic breast cancer; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung |
Details
|
| trastuzumab biosimilar (Hetero) |
Ado-Trastuzumab biosimilar (Hetero) |
Phase 3 Clinical |
Hetero Drugs Ltd |
Neoplasms |
Details
|
| BL-M07D1 |
BLM07D1 |
Phase 3 Clinical |
SystImmune, Sichuan Baili Pharmaceutical Co Ltd |
Solid tumours; Biliary Tract Neoplasms; Ovarian Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Breast Neoplasms; Genital Neoplasms, Female; Endometrial Neoplasms; Urogenital Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Uterine Cervical Neoplasms |
Details
|
| Pertuzumab biosimilar(Zydus Cadila) |
ZRC-3277 |
Phase 3 Clinical |
Zydus Cadila |
Breast Neoplasms |
Details
|
| HL-02 |
HL-02 |
Phase 3 Clinical |
Hualan Genetic Engineering Co Ltd |
Breast Neoplasms |
Details
|
| JSKN-003 |
JSKN-003 |
Phase 3 Clinical |
Alphamab Oncology |
Solid tumours; Neoplasms; Breast Neoplasms |
Details
|
| Pertuzumab biosimilar (Shanghai Henlius Biotech) |
HLX-11 |
Phase 3 Clinical |
Shanghai Henlius Biotech Inc |
Breast Neoplasms; Metastatic breast cancer |
Details
|
| HER2/Neu GP2 vaccine(Greenwich LifeSciences Inc/NuGenerex Immuno Oncology) |
GLSI-100 |
Phase 3 Clinical |
Antigen Express Inc, Norwell Inc |
Breast Neoplasms |
Details
|
| DB-1303 |
BNT323; DB-1303 |
Phase 3 Clinical |
Duality Biologics Co Ltd |
Solid tumours; Breast Neoplasms; Metastatic breast cancer; Endometrial Neoplasms; Neoplasm Metastasis |
Details
|
| Pertuzumab biosimilar (Jushi Biopharmaceutical ) |
SYSA1901; SYSA-1901 |
Phase 3 Clinical |
Jushi Biopharmaceutical Co Ltd |
Breast Neoplasms; Metastatic breast cancer |
Details
|
| Trastuzumab biosimilar(Aprogen/Nichi-Iko) |
AP-06 |
Phase 3 Clinical |
Nichi-Iko Pharmaceutical Co Ltd, Aprogen |
Breast Neoplasms |
Details
|
| Zongertinib |
BI-1810631 |
Phase 3 Clinical |
Boehringer Ingelheim Gmbh |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Breast Neoplasms; Esophageal adenocarcinoma; Lung Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma |
Details
|
| Pertuzumab biosimilar (Xuanzhu/SL) |
KM-118; KM118; XZP-KM118 |
Phase 3 Clinical |
Xuanzhu (Shijiazhuang) Biotechnology Co Ltd, Beijing Sl Pharmaceutical Co Ltd |
Breast Neoplasms |
Details
|
| Pertuzumab biosimilar（Biocon） |
|
Phase 3 Clinical |
Biocon Ltd |
Breast Neoplasms |
Details
|
| Pertuzumab biosimilar (CinnaGen) |
|
Phase 3 Clinical |
Cinnagen |
Breast Neoplasms |
Details
|
| DP-303c |
DP-303c; DP303c |
Phase 3 Clinical |
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd |
Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Salivary Gland Neoplasms; Neoplasms; Breast Neoplasms; Metastatic breast cancer |
Details
|
| Larotinib Mesylate |
Z-650 |
Phase 3 Clinical |
Guangdong Dongyangguang Pharmaceutical Co Ltd |
Solid tumours; Esophageal Neoplasms; Pancreatic Neoplasms; Esophageal Squamous Cell Carcinoma |
Details
|
| DF-1001 |
DF-1001 |
Phase 2 Clinical |
Dragonfly Therapeutics Llc |
Solid tumours |
Details
|
| TPIV-100 (TapImmune) |
TPIV-100 |
Phase 2 Clinical |
Mayo Clinic |
Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Breast Neoplasms, Male |
Details
|
| BB-1701 |
BB-1701 |
Phase 2 Clinical |
Bliss Biopharmaceutical (Hangzhou) Co Ltd |
Solid tumours; Stomach Neoplasms; Carcinoma, Transitional Cell; Breast Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung |
Details
|
| Sapitinib |
AZD-8931 |
Phase 2 Clinical |
Astrazeneca Plc |
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis |
Details
|
| Anti-CD3 and anti-HER2 BiTE-expressing T cell (MedImmune) |
|
Phase 2 Clinical |
University Of Michigan, Huazhong University Of Science And Technology, University Of Virginia Cancer Center, Medimmune |
Breast Neoplasms |
Details
|
| AU-101 |
AU-101 |
Phase 2 Clinical |
Aurora Biopharma |
Glioblastoma; Osteosarcoma; Breast Neoplasms |
Details
|
| Tesevatinib |
XL-647; KD-020; KD-019; EXEL-7647 |
Phase 2 Clinical |
Exelixis Inc |
Glioblastoma; Neoplasms; Brain Neoplasms; Breast Neoplasms; Polycystic Kidney, Autosomal Dominant; Brain metastases; Polycystic Kidney, Autosomal Recessive; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung |
Details
|
| Recombinant anti-HER2 antibody-Tub114 |
DAC-001; DX126-262 |
Phase 2 Clinical |
Hangzhou Dac Biotech Company Ltd |
Stomach Neoplasms; Carcinoma, Transitional Cell; Breast Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung |
Details
|
| AMX-3009 Maleate |
AMX-3009; AMX3009马来酸 |
Phase 2 Clinical |
Anrun Medicine Technology (Suzhou) Co Ltd |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung |
Details
|
| Allitinib Tosylate |
AST-6; ALS-1306; AST-1306 |
Phase 2 Clinical |
Shanghai Allist Pharmaceutical Technology Co Ltd |
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| HLX-22 |
AC-101; HLX-22 |
Phase 2 Clinical |
Shanghai Henlius Biotech Inc, Abclon Inc |
Solid tumours; Stomach Neoplasms; Breast Neoplasms |
Details
|
| Cinrebafusp alfa |
PRS-343 |
Phase 2 Clinical |
Pieris Pharmaceuticals |
Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms |
Details
|
| AU-105 |
AU-105 |
Phase 2 Clinical |
Aurora Biopharma |
Glioblastoma |
Details
|
| Selatinib Ditosilate |
QLNC-120 |
Phase 2 Clinical |
Qilu Antibiotics (Linyi) Pharmaceutical Co Ltd, Qilu Pharmaceutical Co Ltd |
Breast Neoplasms |
Details
|
| HER2 cancer vaccine (BioLife Science) |
PEV-6; PEV-6A; IMU-131 |
Phase 2 Clinical |
Pevion Biotech Ltd |
Esophageal Neoplasms; Stomach Neoplasms; Adenocarcinoma; Gastrointestinal Neoplasms |
Details
|
| Trastuzumab imbotolimod |
BDC-1001 |
Phase 2 Clinical |
Bolt Biotherapeutics Inc |
Solid tumours; Esophageal Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms |
Details
|
| Zenocutuzumab |
MCLA-128 |
Phase 2 Clinical |
Merus Nv |
Solid tumours; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung |
Details
|
| AE-37/GP-2 vaccine |
AE-37 (Generex Biotechnology Corporation) |
Phase 2 Clinical |
Generex Biotechnology Corp |
Triple Negative Breast Neoplasms; Breast Neoplasms |
Details
|
| ORIC-114 |
ORIC-114; VRN-07 |
Phase 2 Clinical |
Voronoi Inc |
Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| YH-32367 |
ABL105; YH-32367 |
Phase 2 Clinical |
Abl Bio Inc |
Solid tumours; Stomach Neoplasms; Breast Neoplasms |
Details
|
| Multiple 4SCAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) |
|
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Breast Neoplasms |
Details
|
| HER2/neu peptide vaccine (Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium) |
|
Phase 2 Clinical |
Fred Hutchinson/University Of Washington Cancer Consortium |
Breast Neoplasms; Breast Neoplasms, Male |
Details
|
| Neratinib (Fukang (Shanghai) Health Technology) |
CVL009; CVL-009 |
Phase 2 Clinical |
Fukang (Shanghai) Health Technology Co Ltd |
Solid tumours; Uterine Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| JSKN-033 |
JSKN033; JSKN-033; JSKN-003/Envafolimab |
Phase 2 Clinical |
Jiangsu Alphamab Biopharmaceuticals Co Ltd |
Solid tumours |
Details
|
| HER2 Targeted HypoSti.CAR-T Cells(Chinese PLA General Hospital) |
|
Phase 2 Clinical |
Pla General Hospital, Fudan University |
Solid tumours |
Details
|
| IBI-354 |
IBI-354 |
Phase 2 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours |
Details
|
| TQB-2102 |
TQB-2102; TQB2102 |
Phase 2 Clinical |
Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group |
Neoplasms; Breast Neoplasms; Metastatic breast cancer |
Details
|
| TQB-2930 |
TQB-2930 |
Phase 2 Clinical |
Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group |
Solid tumours; Neoplasms; Breast Neoplasms |
Details
|
| BAY-2927088 |
BAY-2927088; BAY2927088 |
Phase 2 Clinical |
Bayer AG, Broad Institute, Harvard University |
Carcinoma, Non-Small-Cell Lung |
Details
|
| ST-1703 |
ST-1703 |
Phase 2 Clinical |
Beijing Scitech-Mq Pharmaceuticals Ltd |
Solid tumours; Metastatic breast cancer |
Details
|
| Iodine-131-SGMIB anti-HER2 monoclonal antibody |
[131I]-SGMIB Anti-HER2-VHH1; 131I-SGMIB-anti-HER2-VHH1; Iodine-131-SGMIB-anti-HER2-VHH1; CAM-H2 |
Phase 2 Clinical |
Camel-Ids Nv |
Stomach Neoplasms; Esophageal Neoplasms; Breast Neoplasms |
Details
|
| EO-1001 |
NT-113; APL-122 |
Phase 2 Clinical |
Edison Pharmaceuticals Inc |
Neoplasms |
Details
|
| IMM-2902 |
IMM-2902 |
Phase 2 Clinical |
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd |
Solid tumours; Stomach Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Lung Neoplasms |
Details
|
| AB-201 (Artiva Biotherapeutics) |
|
Phase 2 Clinical |
GC Cell Corp |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Adenocarcinoma |
Details
|
| Fencabtagene autoleucel |
TAC01-HER2 |
Phase 2 Clinical |
Triumvira Immunologics Inc |
Esophageal Neoplasms; Stomach Neoplasms |
Details
|
| Recombinant anti-HER2 humanized HuA21 monoclonal antibody(Hankemab) |
HuA21; HuA-21 |
Phase 2 Clinical |
Hefei Hankemab Biotechnology Co Ltd |
Solid tumours; Stomach Neoplasms |
Details
|
| JRF-103 |
JRF103; JRF-103 |
Phase 2 Clinical |
Shenzhen Jinrui Foundation Biotechnology Co Ltd |
Solid tumours |
Details
|
| IAH-0968 |
IAH-0968; IAH0968 |
Phase 2 Clinical |
SunHo (China) BioPharmaceutical Co Ltd |
Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Colorectal Neoplasms |
Details
|
| AIP-303 |
AIP-303 |
Phase 2 Clinical |
Advanced Imaging Projects |
Breast Neoplasms |
Details
|
| GQ-1001 |
GQ-1001 |
Phase 2 Clinical |
GeneQuantum Healthcare (Suzhou) Co Ltd |
Biliary Tract Neoplasms; Solid tumours; Breast Neoplasms; Metastatic breast cancer |
Details
|
| FCN-411 |
FCN-411 |
Phase 2 Clinical |
Shanghai Fosun Pharmaceutical (Group) Co Ltd |
Small Cell Lung Carcinoma; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| Epertinib |
S-222611 |
Phase 2 Clinical |
Shionogi & Co Ltd |
Neoplasms |
Details
|
| Pirotinib Hydrochloride |
KBP-5209 |
Phase 2 Clinical |
Shandong Xuanzhu Pharmaceutical Technology Co Ltd |
Solid tumours; Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| Gancotamab |
MM-302 |
Phase 2 Clinical |
Merrimack Pharmaceuticals Inc |
Ovarian Neoplasms; Breast Neoplasms |
Details
|
| Anti-CD3-anti-HER2-activated T cells |
|
Phase 2 Clinical |
Transtarget |
Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Prostatic Neoplasms |
Details
|
| HER2/neu cancer vaccine (University of Washington/Corixa/GSK) |
|
Phase 2 Clinical |
University Of Washington |
Ovarian Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Lung Neoplasms; Breast Neoplasms, Male |
Details
|
| anti-HER2 ADC (Pfizer) |
PF-06804103 |
Phase 2 Clinical |
Pfizer Inc |
Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms |
Details
|
| ETBX-021 |
ETBX-021 |
Phase 2 Clinical |
Nantbioscience Inc, Etubics Corp |
Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| HER2(EQ)BBzeta/CD19 T cells (City of Hope) |
|
Phase 1 Clinical |
Mustang Bio Inc, City Of Hope National Medical Center |
Glioma |
Details
|
| RG-6148 |
RG-6148; DHES-0815A |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Breast Neoplasms |
Details
|
| CIDeCAR |
|
Phase 1 Clinical |
Bellicum Pharmaceuticals Inc, National Cancer Institute |
Osteosarcoma |
Details
|
| 99m-Tc labeled anti-HER2 single domain antibody (NanoMab) |
99mTc-NM-02 |
Phase 1 Clinical |
Nanomab Technology Ltd |
Breast Neoplasms |
Details
|
| GB-235 |
GB-235 |
Phase 1 Clinical |
Genor Biopharma Co Ltd |
Breast Neoplasms |
Details
|
| HER-2/Neu pulsed DC1 vaccine (University of Pennsylvania) |
|
Phase 1 Clinical |
University Of Pennsylvania, National Cancer Institute |
Breast Neoplasms |
Details
|
| Anti-HER2 monoclonal antibody-MCC-DM1 conjugate (Shanghai Pharma) |
B-003 (Shanghai Pharma) |
Phase 1 Clinical |
Shanghai Pharmaceuticals Holding Co Ltd, Shanghai Crosslink Pharmaceutical R & D Co Ltd |
Breast Neoplasms |
Details
|
| MP-0274 |
DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274 |
Phase 1 Clinical |
Molecular Partners Ag |
Neoplasms |
Details
|
| 68Ga-anti-HER2 nanobodies (Universite Libre de Bruxelles) |
|
Phase 1 Clinical |
Universite Libre De Bruxelles |
Breast Neoplasms |
Details
|
| KY-1701 |
KY-1701 |
Phase 1 Clinical |
Jiangsu Kanion Pharmaceutical Co Ltd |
Breast Neoplasms |
Details
|
| Recombinant anti-HER2 subdomain II humanized monoclonal antibody(Livzon) |
LZM-005 |
Phase 1 Clinical |
Livzon Pharmaceutical Group Inc |
Breast Neoplasms |
Details
|
| MX-402 |
MX-402 |
Phase 1 Clinical |
Medvax Technologies |
Stomach Neoplasms |
Details
|
| NJH-395 |
NJH-395 |
Phase 1 Clinical |
Novartis Pharma Ag |
Neoplasms |
Details
|
| MB-103 |
MB-103 HER2 CAR; MB-103; HER2(EQ)BBζ/CD19t+ Tcm; HER2-BBζ CAR-T cells |
Phase 1 Clinical |
City Of Hope National Medical Center |
Glioblastoma; Brain metastases |
Details
|
| Fidasimtamab |
IBI-315 |
Phase 1 Clinical |
Hanmi Pharmaceutical Co Ltd, Innovent Biologics(Suzhou) Co Ltd |
Solid tumours; Neoplasms |
Details
|
| Trastuzumab biosimilar (NeuClone/Serum Institute of India) |
|
Phase 1 Clinical |
Serum Institute Of India Ltd, Neuclone |
Stomach Neoplasms; Breast Neoplasms |
Details
|
| RG-6596 |
ZN-1041; RG-6596; ZN-A-1041 |
Phase 1 Clinical |
Suzhou Zanrong Pharmaceutical Technology Co Ltd |
Solid tumours; Breast Neoplasms |
Details
|
| Recombinant anti-HER2 humanized monoclonal antibody complex |
B-002 |
Phase 1 Clinical |
Shanghai Pharmaceuticals Holding Co Ltd |
Breast Neoplasms |
Details
|
| Runimotamab |
BTRC-4017A; RG-6194; RO-7227780 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Solid tumours; Neoplasms |
Details
|
| KSP-910638-G |
KSP-910638G; KSP-910638-G |
Phase 1 Clinical |
University Of Michigan |
Gastrointestinal Neoplasms |
Details
|
| TT-16 |
TT-16 |
Phase 1 Clinical |
Tessa Therapeutics Ltd |
Solid tumours |
Details
|
| SHR-A1201 |
SHR-A1201 |
Phase 1 Clinical |
Jiangsu Hengrui Medicine Co Ltd |
Breast Neoplasms |
Details
|
| M-802(Wuhan Yzy Biopharma/CSPC Pharmaceutical) |
M-802 |
Phase 1 Clinical |
Wuhan Yzy Biopharma Co Ltd, CSPC Pharmaceutical Group Ltd |
Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Breast Neoplasms |
Details
|
| BCD-147 |
BCD-147 |
Phase 1 Clinical |
Biocad |
|
Details
|
| Autologous-HER2-specific-T-cells |
Autologous-HER2-specific-T-cells |
Phase 1 Clinical |
Baylor College Of Medicine |
Sarcoma; Brain Neoplasms |
Details
|
| 14C-labeled poziotinib |
|
Phase 1 Clinical |
Spectrum Pharmaceuticals |
Solid tumours |
Details
|
| Recombinant anti-HER2 human monoclonal antibody-DM1 (Hisun Pharm/Mabworks Biotech) |
HS-630; HS630 |
Phase 1 Clinical |
Zhejiang Hisun Pharmaceutical Co Ltd, Beijing Mabworks Biotech Co Ltd |
Breast Neoplasms |
Details
|
| Puvitinib |
|
Phase 1 Clinical |
Suzhou Teligene Ltd |
Solid tumours |
Details
|
| Anti-HER2 CAR T-cell therapy (Seattle Children's Hospital) |
|
Phase 1 Clinical |
Seattle Children'S Research Institute |
Central Nervous System Neoplasms |
Details
|
| [89Zr]-Df-Trastuzumab |
|
Phase 1 Clinical |
University Of Alabama At Birmingham |
Solid tumours; Neoplasms; Breast Neoplasms |
Details
|
| KSP-QRH-E3-IRDye800 |
|
Phase 1 Clinical |
University Of Michigan |
Cholangiocarcinoma |
Details
|
| Pertuzumab biosimilar(SL Pharma/Combio) |
|
Phase 1 Clinical |
Beijing Kangming Bio New Drug Development Co Ltd, Beijing Sl Pharmaceutical Co Ltd |
Inflammatory Breast Neoplasms; Breast Neoplasms; Metastatic breast cancer |
Details
|
| Recombinant Humanized Anti-Human Epidermal Growth Factor Receptor Monoclonal Antibody and the Dolastatins Derivative DUO5 Conjugated |
ZV0203; ZV203; ADC2122; ADC 2122 |
Phase 1 Clinical |
Zhejiang Hisun Pharmaceutical Co Ltd, Zhejiang Zova Biotherapeutics Inc, Concortis Biosystems Corp |
Solid tumours |
Details
|
| 4-1BBz CD19-Her2tG (Seattle Children's Hospital) |
|
Phase 1 Clinical |
Seattle Children'S Hospital |
Leukemia; Neoplasms; Lymphoma |
Details
|
| HER2.taNK |
NK-92/5.28.z |
Phase 1 Clinical |
Nantkwest Inc |
Glioblastoma |
Details
|
| PB-357 |
PB-357 |
Phase 1 Clinical |
Pfizer Inc |
Neoplasms |
Details
|
| Trastuzumab biosimilar (BioIntegrator) |
BI-Mab-03 |
Phase 1 Clinical |
Biointegrator Llc |
Breast Neoplasms |
Details
|
| BAY-2701438 |
BAY-2701438 |
Phase 1 Clinical |
Bayer AG |
Neoplasms |
Details
|
| Neptinib Di-P-methylbenzenesulfonate |
|
Phase 1 Clinical |
Shenzhen Neptunus Pharmaceutical Research Institute Co Ltd |
Stomach Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| BVAC-B vaccine (Cellid) |
BVAC-B |
Phase 1 Clinical |
Cellid Company |
Stomach Neoplasms |
Details
|
| Trastuzumab biosimilar (Hualan Biological Engineering) |
|
Phase 1 Clinical |
Hualan Genetic Engineering Co Ltd |
Stomach Neoplasms; Breast Neoplasms |
Details
|
| GB-251 |
GB-251; NBT-828; GB221-NBT828 ADC-1 |
Phase 1 Clinical |
Genor Biopharma Co Ltd, Newbio Therapeutics Inc |
Breast Neoplasms; Metastatic breast cancer |
Details
|
| HER.CAR-CMV-specific-CTLs |
HER.CAR-CMV-specific-CTLs |
Phase 1 Clinical |
Baylor College Of Medicine |
Glioblastoma |
Details
|
| ALT-P7 |
HM2-MMAE; ALT-P7 |
Phase 1 Clinical |
Alteogen Inc |
Stomach Neoplasms; Breast Neoplasms |
Details
|
| Autologous AdHER2 dendritic cell vaccine (National Cancer Institute) |
|
Phase 1 Clinical |
National Cancer Institute |
Neoplasms; Breast Neoplasms; Adenocarcinoma; Neoplasm Metastasis |
Details
|
| NC-18 |
NC-18 |
Phase 1 Clinical |
Novacyte Therapeutics Company Ltd |
Solid tumours |
Details
|
| BC-004 |
BC-004 |
Phase 1 Clinical |
Shandong Buchang Pharmaceuticals Co Ltd |
Solid tumours; Breast Neoplasms |
Details
|
| Trastuzumab biosimilar (United BioPharma) |
UB-921 |
Phase 1 Clinical |
United Biopharma Inc |
Breast Neoplasms |
Details
|
| TGFBeta-resistant-HER2-EBV-CTLs |
TGFBeta-resistant-HER2-EBV-CTLs |
Phase 1 Clinical |
Baylor College Of Medicine |
Neoplasms |
Details
|
| ORM-5029 |
ORM-5029 |
Phase 1 Clinical |
Orum Therapeutics Inc |
Solid tumours; Breast Neoplasms |
Details
|
| NeuCeptin |
NeuCeptin |
Phase 1 Clinical |
Neuclone, Serum Institute Of India Ltd |
Stomach Neoplasms; Breast Neoplasms |
Details
|
| XMT-2056 |
XMT-2056 |
Phase 1 Clinical |
Mersana Therapeutics Inc |
Stomach Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| Trastuzumab biosimilar |
CMAB-809 |
Phase 1 Clinical |
Taizhou Maibo Taike Biotechnology Co Ltd |
Breast Neoplasms |
Details
|
| Zanidatamab zovodotin |
ZW-49 |
Phase 1 Clinical |
Zymeworks Inc |
Neoplasms |
Details
|
| Sirotinib Maleate |
XZP-5491 |
Phase 1 Clinical |
Shandong Xuanzhu Pharmaceutical Technology Co Ltd |
Stomach Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung |
Details
|
| IAM-1363 |
IAM-H1; ENT-H1; IAM1363; IAM-1363 |
Phase 1 Clinical |
Iambic Therapeutics Inc |
Neoplasms |
Details
|
| Human HER2-targeted CAR-M cells therapy(Macera therapeutics) |
|
Phase 1 Clinical |
Nanjing Yuanmai Cell Biotechnology Co Ltd, The First People'S Hospital Of Hangzhou, Zju |
Stomach Neoplasms |
Details
|
| AB-201(GC Cell) |
|
Phase 1 Clinical |
GC Cell Corp |
Neoplasms |
Details
|
| [14C]-PLB1004 |
[14C]-PLB1004 |
Phase 1 Clinical |
Beijing Avistone Pharmaceuticals Biotechnology Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
| CT-0525 |
CT-0525 |
Phase 1 Clinical |
Carisma Therapeutics Inc |
Solid tumours |
Details
|
| Anti-HER2-CAR-T Cells Therapy(Simcere Pharmaceutical) |
|
Phase 1 Clinical |
Shanghai Simcere Pharmaceutical Co Ltd, China Medical University, China |
Solid tumours |
Details
|
| IKS014 |
IKS014; IKS-014 |
Phase 1 Clinical |
Iksuda Therapeutics Inc |
Stomach Neoplasms; Esophageal Neoplasms; Digestive System Neoplasms; Breast Neoplasms; Gastrointestinal Neoplasms |
Details
|
| D3L-001 |
D3L-001 |
Phase 1 Clinical |
D3 Bio (Wuxi) Co Ltd |
Solid tumours; Neoplasms |
Details
|
| SNC-109 |
SNC109; SNC-109 |
Phase 1 Clinical |
Shanghai Simnova Biotechnology Co Ltd |
Glioblastoma |
Details
|
| XZP-KM501 |
XZP-KM501; KM-501 |
Phase 1 Clinical |
Xuanzhu (Shijiazhuang) Biotechnology Co Ltd |
Solid tumours; Neoplasm Metastasis |
Details
|
| SMP-656 |
SMP-656 |
Phase 1 Clinical |
Xiling Lab Co Ltd |
Solid tumours; Neoplasms |
Details
|
| ELVN-002 |
ELVN-002 |
Phase 1 Clinical |
Enliven Therapeutics Inc |
Solid tumours; Stomach Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung |
Details
|
| 99mTc-MIRC213 |
99-mTc-MIRC-213 |
Phase 1 Clinical |
Peking Union Medical College Hospital |
Breast Neoplasms |
Details
|
| TY4028 |
TY-4028; TY4028 |
Phase 1 Clinical |
Zhejiang Tongkang Medicine Co Ltd |
Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| FT-825 |
ONO-8250; FT-825; ONO 8250/FT 825 |
Phase 1 Clinical |
Memorial Sloan Kettering Cancer Center |
Solid tumours |
Details
|
| Recombinant human ErbB3 fragment vaccine (Zensun) |
rhErbB3-f |
Phase 1 Clinical |
Zensun (Shanghai) Sci&Tech Co Ltd |
Neoplasms |
Details
|
| SNK-02 |
SNK-02; SNK02 |
Phase 1 Clinical |
NKGen Biotech Inc |
Solid tumours; Neoplasms; Neoplasm Metastasis |
Details
|
| KMHH-03 |
KMHH-03; KMHH03 |
Phase 1 Clinical |
Beijing Kangming Haihui Biological Technology Co Ltd |
Breast Neoplasms |
Details
|
| HF-158-K1 |
HF158K1; HF-158-K1; HF-158K1 |
Phase 1 Clinical |
Hangzhou Gaotian Biological Medicine Co Ltd |
Solid tumours |
Details
|
| FDA022 Antibody Drug Conjugate |
|
Phase 1 Clinical |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd |
Solid tumours |
Details
|
| I-025-A |
I-025-A |
Phase 1 Clinical |
Shanghai Pharmaceuticals Holding Co Ltd |
Breast Neoplasms |
Details
|
| Pertuzumab biosimilar (biocad) |
BCD-178 |
Phase 1 Clinical |
Biocad |
Breast Neoplasms |
Details
|
| 99mTc- ADAPT6 |
99mTc- ADAPT6; ADAPT6; SNA-018 |
Phase 1 Clinical |
Uppsala University, Kth Royal Institute Of Technology |
Breast Neoplasms |
Details
|
| 99mTc-HPArk2 |
99mTc-HPArk2; 99-mTc-HPArk-2 |
Phase 1 Clinical |
Peking Union Medical College Hospital |
Breast Neoplasms |
Details
|
| 99mTc-HE3-G3 |
99mTc-HE3-G3; 99-mTc-HE-3-G-3; 99m-Tc-HE-3-G-3; 99mTc-(HE)3-G3 |
Phase 1 Clinical |
Tomsk National Research Medical Center Of The Russian Academy Of Sciences |
Solid tumours; Breast Neoplasms |
Details
|
| BAY-2701439 |
BAY-2701439 |
Phase 1 Clinical |
Bayer AG |
Neoplasms |
Details
|
| XZP-KM257 |
XZP-KM257; KM257/252; KM-257 |
Phase 1 Clinical |
Beijing Kangming Bio New Drug Development Co Ltd |
Solid tumours |
Details
|
| PM-3002 |
PM-3002 |
Phase 1 Clinical |
Biotheus Inc |
|
Details
|
| XZP-5209 |
XZP-5209 |
Phase 1 Clinical |
Xuanzhu (Shijiazhuang) Biotechnology Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
| GQ-1005 |
GQ-1005; GQ1005 |
Phase 1 Clinical |
GeneQuantum Healthcare (Suzhou) Co Ltd |
Solid tumours; Neoplasms |
Details
|
| SAR-443216 |
SAR-443216 |
Phase 1 Clinical |
Sanofi |
Solid tumours; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Lung Neoplasms |
Details
|
| NIP-142 |
NIP-142 |
Phase 1 Clinical |
National Institutes Of Pharmaceutical Research And Development Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
| TAS-2940 |
TAS-2940 |
Phase 1 Clinical |
Taiho Oncology Inc |
Solid tumours; Glioblastoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| Anti-HER2 CAR T-cell therapy (Baylor College of Medicine/The Hospital for Sick Children/Texas Children's Hospital/The Methodist Hospital System ) |
|
Phase 1 Clinical |
Baylor College Of Medicine, The Hospital For Sick Children, Texas Children'S Hospital, The Methodist Hosp Research Institute |
Sarcoma |
Details
|
| SSGJ-705 |
705; SSGJ-705 |
Phase 1 Clinical |
Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd |
Solid tumours; Neoplasms |
Details
|
| HER-2 Specific CAR T Cell |
|
Phase 1 Clinical |
Pediatric Brain Tumor Consortium (Pbtc), St. Jude Children'S Research Hospital |
Ependymoma |
Details
|
| SPH-5030 |
SPH-5030 |
Phase 1 Clinical |
Shanghai Pharmaceuticals Holding Co Ltd |
Solid tumours |
Details
|
| 89Zr-ss-Pertuzumab |
|
Phase 1 Clinical |
Genentech Inc |
Breast Neoplasms; Metastatic breast cancer |
Details
|
| SSGJ-612 |
SSGJ-612 |
Phase 1 Clinical |
Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd |
Solid tumours |
Details
|
| Pertuzumab biosimilar(EirGenix) |
EG-1206A; EG-1206-A |
Phase 1 Clinical |
Eirgenix Inc |
Breast Neoplasms |
Details
|
| Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University) |
|
Phase 1 Clinical |
Sichuan University |
Peritoneal Neoplasms; Pleural Effusion, Malignant |
Details
|
| CT-0508 |
CT-0508 |
Phase 1 Clinical |
Carisma Therapeutics Inc |
Solid tumours |
Details
|
| CCT303-406 |
|
Phase 1 Clinical |
Shanghai Sinobioway Sunterra Biotech |
Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Breast Neoplasms; Sarcoma |
Details
|
| BAT-1006 |
BAT-1006 |
Phase 1 Clinical |
Bio-Thera Solutions Ltd |
Solid tumours |
Details
|
| EX-101 |
EX-101; EX101 |
Phase 1 Clinical |
Guangzhou Excelmab Inc |
Solid tumours |
Details
|
| DZD-1516 |
DZD-1516 |
Phase 1 Clinical |
Dizal (Jiangsu) Pharmaceutical Co Ltd |
Breast Neoplasms; Metastatic breast cancer |
Details
|
| MBS-301 |
MBS-301 |
Phase 1 Clinical |
Beijing Mabworks Biotech Co Ltd |
Solid tumours; Stomach Neoplasms; Breast Neoplasms |
Details
|
| ACE-1702 |
ACE-1702 |
Phase 1 Clinical |
Acepodia Taiwan Subsidiary |
Solid tumours; Stomach Neoplasms; Metastatic breast cancer; Neoplasm Metastasis |
Details
|
| Pertuzumab biosimilar (Hengrui Pharma) |
SHR-1309 |
Phase 1 Clinical |
Jiangsu Hengrui Medicine Co Ltd |
Metastatic breast cancer |
Details
|
| Recombinant anti-HER2 humanized monoclonal antibody (Shenzhen Main Luck Pharmaceuticals) |
|
Phase 1 Clinical |
Shenzhen Main Luck Pharmaceuticals Inc |
Breast Neoplasms |
Details
|
| Recombinant anti-HER2 domain II humanized monoclonal antibody (Qilu Pharmaceutical) |
|
Phase 1 Clinical |
Qilu Pharmaceutical Co Ltd |
Breast Neoplasms |
Details
|
| Trastuzumab biosimilar (BioXpress) |
BXT-2318; BX-2318 |
Clinical |
Bioxpress Therapeutics Sa |
Stomach Neoplasms; Metastatic breast cancer |
Details
|
| IBPM003TZ (Inbiopro Solutions) |
IBPM-003TZ |
Clinical |
Inbiopro Solutions |
Breast Neoplasms |
Details
|
| IBPM002BZ (Inbiopro Solutions) |
IBPM-002BZ |
Clinical |
Inbiopro Solutions |
Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms |
Details
|
| 99mTc-DARPinG3 |
99mTc-DARPinG3; 99mTc-DARPinG-3 |
Clinical |
Tomsk National Research Medical Center Of The Russian Academy Of Sciences |
Breast Neoplasms |
Details
|
| 99mTc-MIRC208 |
|
Clinical |
Beijing Cancer Hospital |
Neoplasms |
Details
|
| [18F]GE-226 |
GE-226-[18F]; Fluorine-18-GE-226; [18F]GE-226 |
|
Affibody Ab |
|
Details
|
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one. 
A-Z
